Table 1 Patient demographics and baseline clinical data
From: Right ventricular myocardial deoxygenation in patients with pulmonary artery hypertension
Variables | PAH (n = 42) | Healthy Controls (n = 11) | p-value |
|---|---|---|---|
Age (years), median (range) | 71 (63–79) | 66 (60–69) | 0.123 |
Females sex, n (%) | 27 (68%) | 4 (36%) | 0.061 |
Comorbidities | |||
 Hypertension, n (%) | 22 (52%) | 0 |  |
 Diabetes, n (%) | 7 (17%) | 0 |  |
 Dyslipidaemia, n(%) | 13 (31%) | 0 |  |
 Chronic Obstructive Airways Disease, n (%) | 10 (24%) | 0 |  |
 Obstructive Sleep Apnoea, n (%) | 11 (26%) | 0 |  |
 Atrial Fibrillation, n (%) | 8 (19%) | 0 |  |
Right heart catheter haemodynamic indices | |||
 Mean pulmonary artery pressures (mmHg), median (range) | 33 (16–57) | 0 |  |
 Pulmonary artery wedge pressure (mmHg), median (range) | 12 (4–15) | 0 |  |
 Mean right atrial pressures (mmHg), median (range) | 12 (2–18) | 0 |  |
 Cardiac index (L/min/m2), median (range) | 3 (2–4) | 0 |  |
Pulmonary vascular resistance index (Woods unit m2), median (range) | 7 (3–28) | 0 |  |
Medication | |||
 Aspirin, n (%) | 6 (14%) | 0 |  |
 Beta-blockers, n (%) | 10 (24%) | 0 |  |
 ACEi/ARB, n (%) | 12 (29%) | 0 |  |
 Statins, n (%) | 8 (19%) | 0 |  |
 Calcium channel blockers | 13 (31%) | 0 |  |
 Endothelin receptor blockers, n (%) | 34 (81%) | 0 |  |
 PDE5 inhibitor, n (%) | 18 (43%) | 0 |  |
 Soluble guanylate cyclase, n (%) | 3 (7%) | 0 |  |
 Combination therapy, n (%)a | 14 (33%) | 0 |  |